Top Markets
#1 PulseChain PulseChain +45.01%
#2 RedStone RedStone +18.29%
#3 Glidr Glidr +11.78%
#4 SkyAI SkyAI +10.14%
#5 Bitway Bitway +9.91%
#6 OPENLOOT OPENLOOT +8.85%
#7 Pump.fun Pump.fun +7.99%
#8 Unit Pump Unit Pump +7.99%
#9 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.84%
#10 Monad Monad +6.79%
Coin of the day
PulseChain PulseChain
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Rang in aandelen #28046
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Aandeelprijs
$0.55
Laatst gesynchroniseerd: 2025-02-11
Marktkapitalisatie
$28.90M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Categorie

Healthcare
Omzet van Marinus Pharmaceuticals, Inc. (MRNS)
Omzet in Sep 2024 TTM: $31.47M
Volgens de laatste financiële rapporten van Marinus Pharmaceuticals, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $31.47M. In 2022 behaalde het bedrijf een omzet van $25.48M een stijging ten opzichte van de omzet in het jaar 2021, die $15.35M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Marinus Pharmaceuticals, Inc. van 2012 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
2026 (TTM) $31.47M 1.54%
2023 $30.99M 21.63%
2022 $25.48M 66.03%
2021 $15.35M 793.19%
2020 $1.72M 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 $100.00K 0.00%
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 40,020.45%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 6,980.66%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 19,035.85%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 49,779.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH